RCKT Stock Analysis: Buy, Sell, or Hold?
RCKT - Rocket Pharmaceuticals, Inc. Common Stock
$3.84
0.32 (9.09%)
▲
5d:
+18.52%
30d:
+32.87%
90d:
+6.08%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When RCKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: RCKT is 13.3% above its trading range ($3.39). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: RCKT is 13.3% above its trading range ($3.39). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: RCKT is currently trading at $3.84, which is considered extended relative to its 30-day fair value range of $2.76 to $3.39.
Technical Outlook: Technically, RCKT is in a uptrend. The price is approaching resistance at $3.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.1% recently.
Market Sentiment: RCKT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.39 (+144.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RCKT is in a uptrend. The price is approaching resistance at $3.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.1% recently.
Market Sentiment: RCKT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.39 (+144.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.76 -
$3.39
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+13.3% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.1%)
- BULLISH: Trading 144.4% below Wall St target ($9.39)
Trading Range Analysis
30-Day Trading Range
$2.76 -
$3.39
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.08
Resistance Level
$3.78
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.30
Wall Street Target
$9.39
(+144.4%)
Share & Embed Analysis
Last updated: July 02, 2026 10:42 PM ET
Data refreshes hourly during market hours. Next update: 11:42 PM
Data refreshes hourly during market hours. Next update: 11:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RCKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
John Militello
SELL
1157 shares
2026-02-18
Gaurav Shah
SELL
12279 shares
2026-02-13
John Militello
SELL
3726 shares
2026-02-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
